Preoperative Systemic Therapy Versus Upfront Surgery in HER2-Positive Breast Cancer in the Real World

Xingfei Yu, Chen Wang, Yabing Zheng, Beibei Miao, Jiejie Hu, Xiying Shao, Liming Sheng, Juan Lin, Yuqin Ding, Haojun Xuan, Yingying Ding, Lijie Gong, Weiliang Feng, Chengdong Qin, Daobao Chen, Yu Yang, Hongjian YangFrontiers in Oncology 2021 · DOI

TL;DR

This study investigates whether preoperative systemic therapy (PST) improves survival outcomes for HER2-positive early breast cancer patients compared to upfront surgery. While initial analysis showed upfront surgery as superior, after rigorous statistical adjustments for patient characteristics, PST was found to significantly improve disease-free survival, particularly for patients achieving a pathological complete response.

What Problem Does This Paper Address?

The optimal treatment strategy for HER2-positive early breast cancer remains a subject of ongoing research. Preoperative systemic therapy (PST), which involves chemotherapy and targeted HER2 therapies (like trastuzumab) before surgery, has gained popularity. It offers potential benefits such as downstaging the tumor, enabling breast-conserving surgery, and identifying patients who respond well to treatment. However, historical trials (like NSABP B-18/27) using only chemotherapy did not show improved survival with PST. More recent studies suggest that adding HER2-targeted agents to PST can increase pathological complete response (pCR) rates, but whether this translates to improved long-term survival compared to upfront surgery in real-world settings is not fully established. This paper aims to address this gap by comparing survival outcomes between PST and upfront surgery in a large cohort of HER2-positive early breast cancer patients treated between 2012 and 2015.

Methods

The researchers conducted a real-world, retrospective study using data from patients diagnosed with HER2-positive early invasive breast cancer between 2012 and 2015. Patients were categorized into two groups based on their actual initial treatment: preoperative systemic treatment (PST) or upfront surgery (US).

To account for potential confounding factors that could bias the comparison between these two groups, the study employed advanced statistical methods:

  • Propensity Score Matching (PSM): This technique aims to create comparable groups by matching patients in the PST group with similar patients in the US group based on a range of clinicopathological characteristics (age, stage, grade, ER/PR status). A 1:1 matching ratio was used.
  • Inverse Probability of Treatment Weighting (IPTW): This method assigns weights to each patient based on their probability of receiving their assigned treatment. This effectively creates a "pseudo-population" where treatment groups are balanced across observed covariates.

The primary endpoint was disease-free survival (DFS), defined as the time from enrollment to recurrence, contralateral breast cancer, or death without evidence of breast cancer. Overall survival (OS) was the secondary endpoint. Kaplan-Meier curves were used to estimate survival, and hazard ratios were calculated to assess the risk of events.

Datasets

The study utilized a real-world dataset of 1,067 HER2-positive early breast cancer patients treated at the Cancer Hospital of the University of Chinese Academy of Sciences and Taizhou Cancer Hospital between 2012 and 2015. This dataset was collected prospectively for treatment assignment but analyzed retrospectively.

Key Insights and Ideas

  • The "Real World" Matters: Traditional randomized controlled trials (RCTs) have limitations in reflecting actual clinical practice. This study's strength lies in its real-world data, capturing the heterogeneity of treatments and patient characteristics encountered daily.
  • Statistical Adjustment is Crucial: Initial unadjusted analysis suggested upfront surgery was better. However, after sophisticated statistical adjustments (PSM and IPTW), the picture changed dramatically, highlighting the importance of controlling for confounding variables in observational studies.
  • pCR is a Strong Predictor: The study reinforces the known prognostic value of pathological complete response (pCR) after PST. Patients achieving pCR in the PST group had excellent survival, even outperforming the upfront surgery group in some analyses. This suggests that PST's benefit might be largely driven by its ability to achieve pCR and identify patients with a favorable prognosis.
  • DFS is the Key Differentiator: While OS showed no significant difference between the groups even after adjustments, DFS emerged as the primary outcome where PST demonstrated a significant advantage in the matched and weighted analyses. This implies that PST might be more effective at preventing recurrence than at prolonging life in the long term, or that differences in OS take longer to manifest.

Key Results

  • Unweighted Analysis: In the initial, unadjusted analysis of 1,067 patients (215 PST, 852 US), the upfront surgery (US) group had a significantly better DFS (HR 1.828) and a trend towards better OS (HR 1.607) compared to the PST group.
  • Propensity Score Matching (PSM): After matching 145 pairs of patients, the PST group showed a significantly higher DFS (HR 0.572, P=0.012) compared to the US group. No significant difference in OS was observed.
  • Inverse Probability of Treatment Weighting (IPTW): Using IPTW on a larger weighted sample, no significant difference in DFS (HR 0.946) or OS was found between the PST and US groups.
  • Stratified Analysis (pCR): In the PST group, patients who achieved pCR had significantly better DFS and OS compared to those who did not achieve pCR. Furthermore, patients who achieved pCR after PST had comparable or better DFS than the US group.

Limitations and Future Work

The authors acknowledge several limitations:

  • Chemotherapy Regimen Heterogeneity: The study could not pre-determine or balance chemotherapy regimens across groups due to the real-world nature of the data, making statistical analysis challenging.
  • Anti-HER2 Treatment Limitations: The study period predates the widespread availability of pertuzumab in China, meaning the PST group primarily received trastuzumab plus chemotherapy, which might be considered suboptimal by current standards.
  • Reduced Power with PSM: While PSM is a powerful tool for controlling confounders, it reduces the sample size and can thus decrease statistical power.

Future work could involve analyzing data from periods where more advanced anti-HER2 therapies were standard, or conducting prospective studies to further validate these findings and explore optimal PST regimens. The study also suggests that identifying high-risk patients who benefit most from PST is crucial, as it can guide adjuvant strategies and potentially improve outcomes beyond what upfront surgery alone can achieve.

Summary updated

Abstract

Purpose To compare survival in different strategies, preoperative systemic treatment versus upfront surgery, in HER2-positive early breast cancer patients in the real world. Methods According to the actual upfront treatment, eligible patients from 2012 to 2015 were classified as preoperative systemic treatment or upfront surgery group prospectively. The primary endpoint is disease-free survival; the second endpoint is overall survival. All the outcomes were examined in the propensity score matching model and inverse probability of treatment weighting model. Results Included in the analysis were 1,067 patients (215 in the preoperative systemic treatment group, 852 in the upfront surgery group). In the propensity score matching model (matching at 1:1 ratio), the disease-free survival of the preoperative systemic treatment group was significantly higher than that of the upfront surgery group (hazard ratio, 0.572, 95%CI, 0.371–0.881, P , 0.012). In the inverse probability of treatment weighting model, there was no significant difference in disease-free survival between the two groups (hazard ratio, 0.946, 95%CI, 0.763–1.172, P , 0.609). For overall survival, there was no significant difference between the two groups. Conclusion The HER2-positive patients who accepted preoperative systemic treatment had better disease-free survival than those who underwent upfront surgery by real-world statistic methods. Clinical Trial Registration Clinicaltrials.gov , identifier NCT04249440.
BibTeX
@inproceedings{yu2021preoperative,
  author = {Xingfei Yu and Chen Wang and Yabing Zheng and Beibei Miao and Jiejie Hu and Xiying Shao and Liming Sheng and Juan Lin and Yuqin Ding and Haojun Xuan and Yingying Ding and Lijie Gong and Weiliang Feng and Chengdong Qin and Daobao Chen and Yu Yang and Hongjian Yang},
  title = {{Preoperative Systemic Therapy Versus Upfront Surgery in HER2-Positive Breast Cancer in the Real World}},
  booktitle = {Frontiers in Oncology},
  year = {2021},
  doi = {10.3389/fonc.2021.704842},
}
Figure